Zuoyi Jiao

MD, Professor, Chief Physician

Tel：

+86-13893415219

Fax：

0931-8458109

E-Mail：

jiaozy@lzu.edu.cn

Group Homepage：

No. 82 Cuiyingmen Lanzhou, Gansu province, P R. China.

· Honors and Rewards

2023                      Gansu Province's Top Leading Talents

2021                      The Second Prize of Gansu Province Science and Technology Progress Award 

2018                      Gansu Province Youth Science and Technology Award

2018                      Gansu Province Medical Science and Technology Award

2016                      The Second Prize of Gansu Province Science and Technology Progress Award

2015                      Gansu Province Medical Science and Technology Award 

· Research Topics

Digestive system tumors; New drug development

Based on the major goals of the Healthy China 2030 plan concerning “how to improve the 5-year survival rate of digestive system cancers in the era of target-immune therapy,” we have conducted systematic research focusing on “the mechanisms of drug resistance in gastric cancer/pancreatic cancer and the development of new drugs.”

· Selected Publications

1. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress. Jiang X, Ma Y, Wang T, Zhou H, Wang K, Shi W, Qin L, Guan J, Li L, Long B, Wang J, Guan X, Ye H, Yang J, Yu Z, Jiao Z*. Gastroenterology 2023, 164, 1232-1247.

2. PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer. Ye H, Shi W, Yang J, Wang L, Jiang X, Zhao H, Qin L, Qin J, Li L, Cai W, Guan J, Yang H, Zhou H, Yu Z, Sun H, Jiao Z*.   Cancer Res. 2023, 83, 3767-3782.

3. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, Cai W, Wen F, Jiang X, Zhang T, Ye H, Long B, Qin J, Shi W, Guan X, Yu Z, Yang J, Wang Q, Jiao Z*. Sci. Adv. 2022, 8, eabn3774.

4. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.  Shi W, Zhang G, Ma Z, Li L, Liu M, Qin L, Yu Z, Zhao L, Liu Y, Zhang X, Qin J, Ye H, Jiang X, Zhou H, Sun H, Jiao Z*. Nat. Commun. 2021, 12, 2812.

5. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren W, Li H, Zhao L, Liu H, Yan H, Shi W, Wang Q, Luo C, Long B, Zhou H, Sun H, Jiao Z*. Oncogene 2021, 40, 1027-1042.